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Background: The preventive effect of fluralaner chewable tablets (Bravecto™) against transmission of Babesia canis
by Dermacentor reticulatus ticks was evaluated.
Methods: Sixteen dogs, tested negative for B. canis by PCR and IFAT, were allocated to two study groups. On
day 0, dogs in one group (n = 8) were treated once orally with a fluralaner chewable tablet according to label
recommendations and dogs in the control group (n = 8) remained untreated. On days 2, 28, 56, 70 and 84,
dogs were infested with 50 (±4) B. canis infected D. reticulatus ticks with tick in situ thumb counts 48 ± 4 h
post-infestation. Prior to each infestation, the D. reticulatus ticks were confirmed to harbour B. canis by PCR analysis.
On day 90, ticks were counted and removed from all dogs. Efficacy against ticks was calculated for each assessment
time point. After treatment, all dogs were physically examined in conjunction with blood collection for PCR every
7 days, blood samples for IFAT were collected every 14 days and the dog’s rectal body temperature was measured
thrice weekly. From dogs displaying symptoms of babesiosis or were PCR positive, a blood smear was taken, and,
if positive, dogs were rescue treated and replaced with a replacement dog. The preventive effect was evaluated by
comparing infected dogs in the treated group with infected dogs in the untreated control group.
Results: All control dogs became infected with B. canis, as confirmed by PCR and IFAT. None of the 8 treated
dogs became infected with B. canis, as IFAT and PCR were negative throughout the study until day 112. Fluralaner
chewable tablet was 100 % effective against ticks on days 4, 30, 58, and 90 and an efficacy of 99.6 % and 99.2 %
was achieved on day 72 and day 86 after treatment, respectively. Over the 12-week study duration, a 100 %
preventive effect against B. canis transmission was demonstrated.
Conclusions: A single oral administration of fluralaner chewable tablets effectively prevented the transmission of B.
canis by infected D. reticulatus ticks over a 12-week period.
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Canine babesiosis, caused by protozoa of the genus
Babesia through the bite of a vector tick, is a clinically
important tick-borne disease. In Europe to date, four
Babesia species known to affect dogs have been identi-
fied. Babesia canis, Babesia vogeli, Babesia gibsoni and
Babesia vulpes sp. nov., previously known as Babesia
microti-like [1–3]. Of these species, B. canis is the most
widely distributed in Europe, coinciding with the distri-
bution of its known vector Dermacentor reticulatus, the
ornate dog tick. B. vogeli is most often found around the
Mediterranean basin where Rhipicephalus sanguineus is
the predominant tick species. The Babesia vulpes sp.
nov. species seems to be centered in the northwest of
Spain whereas the occurrence of B. gibsoni is reported
more sporadically [2, 4].
Babesia spp. are intracellular protozoa habiting in the
red blood cells of the host. The clinical signs of babesiosis
in dogs vary from mild transient illness to acute disease
due to severe haemolysis that rapidly results in death.
Clinical findings include pale mucus membranes, elevated
body temperature, anorexia, icterus, pyrexia, and splenic
and hepatic enlargement [2]. However, the severity of the
disease depends on various factors such as the Babesia
species involved, the age and immune status of the dog
and the presence of other infectious diseases [4].
Worldwide, canine babesiosis is one of the most emi-
nent tick-borne diseases [5]. Due to increasing pet own-
ership, more owners travelling with their pets and the
ability of vector arthropods to establish themselves in
new localities [6], ticks and tick-borne diseases are spread-
ing throughout the world and are no longer restricted to
certain areas.
Once the infected tick has attached to the dog, the risk
of pathogen transmission from the tick to the dog is in-
creased by sustained feeding. In most tick-borne disease
systems, after initial tick attachment, a feeding period of
at least 24 to 48 h is required before transmission of
protozoa occur [7]. To prevent the pathogen transmission,
it is necessary to kill the infected tick within this time
period. To quantify the dynamics of transmission of tick-
borne pathogens, transmission blocking tick models have
been developed. Such a model includes a sufficient
number of treated dogs to test the duration of prevent-
ive activity, plus an untreated control group wherein the
majority of dogs become infected with the tick-borne
pathogen.
In the current study, dogs were treated once orally
with fluralaner chewable tablets (Bravecto™). Fluralaner,
a new ectoparasiticide in the novel isoxazoline com-
pound class, elicits its primary action through feeding
activity, with a duration of efficacy over 12 weeks result-
ing in the immediate and persistent killing of ticks and
fleas on dogs [8]. As fluralaner is a systemic actingectoparasiticide; its efficacy depends on ticks attaching
to the host’s skin and commencing to feed, thereby
ingesting the active compound. Due to its rapid speed of
killing within 12 h after tick attachment [9], the potential
of orally administered fluralaner to prevent B. canis
transmission was tested in the outlined study.
Methods
Study set-up
The study was conducted in accordance with Good
Clinical Practice (VICH guideline GL9, Good Clinical
Practice, EMA, 2000), and was in compliance with the
South African National Standard “SANS 10386:2008:
The care and use of animals for scientific purposes” and
ethical approval was obtained by the ClinVet Animal
Ethics Committee (CAEC) before the study start. The
study was performed as a negative controlled, partly
blinded, randomized efficacy study.
Sixteen mixed breed dogs (8 males, 8 females) tested
negative for babesial DNA by PCR analysis and negative
for B. canis antibodies (IFAT) before treatment were used.
All dogs included were between 1 and 8 years of age and
weighed between 13.2 and 26.9 kg. Each dog was in good
health; had not been treated with any parasite control
product within 3 months prior to a 7-day acclimatization
period; did not harbour any ticks before treatment; and
was uniquely identified by a microchip number.
Prior to randomization, dogs were clinically examined
and weighed. Dogs were ranked within gender by de-
scending body weight and randomly allocated to two study
groups (one treatment and one control group) of 8 dogs
each using a computer-generated randomization list.
All dogs were kept indoors and housed individually
during the study course. Temperature in the dog hous-
ing facility ranged between 15.1 and 27.9 °C and the
relative humidity between 21.9 and 66.4 %. All dogs were
fed a standard commercially available dry dog food once
daily and drinking water was provided ad libitum.
Treatment
On day 0 (i.e., day of treatment), dogs in the treatment
group were treated once orally with fluralaner chewable
tablets (Bravecto™), according to label recommendations.
Each dog received half of its daily food ration approxi-
mately 20 min before administration of treatment and
the balance directly after treatment. The chewable tablet
was administered by placement in the back of the oral
cavity over the tongue to initiate swallowing. Each treated
dog was continuously observed for 1 h after administra-
tion to monitor for vomit or tablet spit out, which did not
occur in any of the 8 dogs. Dogs in the control group
remained untreated. Specific health observations on day 0
were performed hourly, up to 4 h after administration on
all dogs (treated and untreated).
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A laboratory-bred D. reticulatus tick isolate (European
origin) infected with B. canis was used for each infest-
ation. Tick infestations were conducted on all dogs on
days 2, 28 (4 weeks), 56 (8 weeks), 70 (10 weeks), and 84
(12 weeks). One sample of D. reticulatus ticks (approxi-
mately 50) was taken from each batch of ticks used for
each infestation to determine the percentage of infection
with B. canis by PCR analysis. At each infestation time
point, each dog was infested with 50 (± 4) viable, unfed
adult D. reticulatus ticks (50 % female; 50 % male). Dogs
were not sedated for infestation, but during each infest-
ation every dog was placed in an infestation restrainer
measuring 90 × 80 × 70 cm (L x W x H) and ticks were
manually applied to the animal’s fur; thereafter the
animals were restrained for approximately 10 min. Dur-
ing this time ticks which fell off from the animal were
re-applied. After 10 min the infestation restrainer was
closed, and after 4 h (± 10 min) the dog was released
into its cage.
Tick in situ thumb counts were performed on each
dog at 48 ± 4 h post each infestation (i.e., on days 4, 30,
58, 72, and 86), but ticks were not removed. On day 90,
all remaining ticks on each dog were removed and
counted. The personnel conducting tick infestation, tick
in situ counting and tick removal on day 90 were blinded
to the treatment status of each dog.
Animal health
To monitor each dog closely for any signs of canine
babesiosis, each dog was physically examined by a veter-
inarian on a 7-day interval until completion of the study
(i.e., days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91,
98, 105, and 112). Starting on day 8 after treatment, the
rectal body temperature of each dog was measured
thrice weekly. General health observations, noting the
dog as normal or abnormal, were performed once daily
throughout the complete study duration (i.e., starting 7
days prior to treatment until day 112 after treatment).
If a dog was noted as abnormal or the rectal body
temperature was measured above or equal to 39.4 °C,
an additional physical examination by a veterinarian
was performed. If one or more parameters were ob-
served as abnormal during this examination, a blood
sample for blood smear performance was collected.
The blood smear was air dried and stained with a Diff-
quick Stain Kit prior to evaluation.
Blood for serology (IFAT) and PCR analysis
Blood samples for serum analysis for B. canis antibodies
were collected on a 14-day interval, starting on day 14
after treatment. IFATs were performed using the “Mega-
Screen® FLUOBABESIA canis” commercial kit. All sera
were diluted at 1:80 and were recorded as positive ifspecific fluorescence was observed, or negative if no
fluorescence was observed.
Blood samples for PCR analysis regarding B. canis
DNA were collected in EDTA tubes from each dog on a
7-day interval. Total genomic DNA was isolated from
whole blood samples using a commercial genomic DNA
isolation kit (GeneJet Genomic DNA Purification kit,
Thermo Scientific). PCR entailed the use of primers
Babesia2F (5′-GGAAGGAGAAGTCGTAACAAGGTTT
CC-3′) and Bcanis2R (5′-CAGTGGTCACAGACCGG
TCG-3′) with combined specificity to the B. canis ITS1
region of the DNA in order to amplify a target region of
302 bp [10]. Up to 400 ng isolated DNA served as tem-
plate for PCR amplification of the target region. PCR
products were analysed using agarose gel electrophor-
esis. A PCR product of approximately 300 bp indicated
the presence of the target region in the sample. To verify
PCR success in each individual tube, positive, negative,
no templates as well as internal amplification controls
were included in each run.
Rescue treatment
A blood sample for blood smear performance was col-
lected from each dog displaying a rectal body temperature
above or equal to 39.4 °C, or with a positive PCR analysis
result for babesial DNA, or clinical signs of babesiosis ob-
served during physical examination. Dogs confirmed posi-
tive for B. canis protozoa by blood smear were rescue
treated and received the appropriate treatment with dimin-
azene (Berenil; MSD Animal Health) at a dosage of 1 mL/
20 kg body weight on the first day and with imidocarb
(Forray 65; MSD Animal Health) at a dosage of 1.2 mL/20
kg body weight on the next day. A rescue-treated dog
remained part of all health observations (i.e., general
health, rectal body temperature assessment, physical
examination) but was not subjected to subsequent tick
infestations. This dog was moved from the study hous-
ing facilities to an outdoor run exposed to ambient en-
vironmental conditions, and group housed until final
study exclusion. Before moving, all ticks were removed.
Blood samples for PCR and IFAT were collected and after
confirmation of a babesial infection by both analysis
methods, this dog was finally excluded from the study.
Replacement dogs
Due to the several planned tick infestation time points
during the study duration (i.e., tick infestations on days
2, 28, 56, 70, and 84), in addition to the 8 primary in-
cluded dogs in the control group, replacement dogs were
included as required, and to replace animals in this
group rescue treated for babesiosis. Before study inclusion,
a replacement dog was acclimatized for 7 days prior to
first tick infestation for that animal. During this period the
dog was tested negative for B. canis by PCR analysis and
Table 1 Mean tick counts and efficacy against ticks after single
oral treatment with fluralaner chewable tablets
Day 4 Mean tick countsa (control/treated) [n] 18.6/0.0
Efficacy [%] 100b
Day 30 Mean tick countsa (control/treated) [n] 18.8/0.0
Efficacy [%] 100b
Day 58 Mean tick countsa (control/treated) [n] 12.7/0.0
Efficacy [%] 100b
Day 72 Mean tick countsa (control/treated) [n] 22.2/0.1
Efficacy [%] 99.6b
Day 86 Mean tick countsa (control/treated) [n] 23.0/0.2
Efficacy [%] 99.2b
Day 90 Mean tick countsa (control/treated) [n] 22.3/0.0
Efficacy [%] 100b
aGeometric mean live attached ticks
bLog-counts of ticks from the treated group were significantly different
(p < 0.0001) from log-counts of the untreated control group
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performed. Replacement dogs were not randomized, but
whenever possible the replacement dog had the same sex
as the control dog replaced.
Efficacy evaluation
The statistical analysis was performed using the software
package SAS® (SAS Institute Inc., Cary, NC, USA, re-
lease 9.3). The individual dog was the experimental unit
in all statistical calculations. Data from each tick in situ
thumb count time point were analysed separately.
The percentage of efficacy against ticks was calculated
for the treatment group at each assessment time point
using geometric means with Abbott’s formula:
Efficacy (%) = 100 × (MC - MT)/MC, where MC was the
mean number of total live attached ticks on untreated
control dogs and MT the mean number of total live at-
tached ticks on treated dogs. In case of zero counts, the








Significant differences were assessed between the log-
counts of live attached ticks in the treated group at each
assessment time point and the log-counts of the untreated
control group. Study groups were compared using a linear
mixed model including study group as a fixed effect and
block as a random effect. The two-sided level of signifi-
cance was declared when P ≤ 0.05.
The percentage of preventive effect against B. canis
transmission for the treatment group was calculated as
follows: Preventive effect (%) = 100 × (TC - TT)/TC,
where TC is the total number of infected dogs in the un-
treated group and TT is the total number of infected
dogs in the treated group. A dog was regarded infected
with B. canis, if it was tested serologically positive for B.
canis antibodies (IFAT) and positive for B. canis DNA in
PCR assay.
Results
No treatment-related adverse events were observed in
any of the 8 dogs treated orally with fluralaner during
the 12-week post-treatment observation period. In total
19 replacement dogs (10 male, 9 female) were included
in the control group throughout the study, ensuring that
at each tick infestation time point, the control group
consisted of 8 animals, which was possible for all infest-
ation time points except the last one on day 84. For tick
challenge on day 84 only 6 control animals were available,
from which two were tested positive by blood smear and
PCR analysis on day 85 and rescue treated, so that for tick
in situ thumb counting on day 86 the control groupconsisted of 4 animals. Efficacy calculation for day 86 and
day 90 were therefore calculated with 4 control dogs. The
mean tick counts and the detailed efficacy against ticks
are shown in Table 1. An efficacy against ticks at each as-
sessment time point between 99.2 and 100 % was achieved
after single oral fluralaner treatment.
None of the dogs treated with Bravecto™ chewable tab-
lets developed any clinical signs referring to babesiosis.
Dogs in the control group developed clinical signs refer-
ring to babesiosis as pale mucous membranes, rectal body
temperature above or equal to 39.4 °C, depressed/listless
general behaviour, enlarged lymph nodes and enlarged
spleen.
Rectal body temperatures were measured for each dog
thrice weekly. In 19 of 27 control dogs a rectal body
temperature above or equal to 39.4 °C was measured on
at least one measurement time point during the study.
In the treated group in 1 of 8 dogs a rectal body
temperature above or equal to 39.4 °C was measured
once 17 days after treatment. This elevated rectal body
temperature was not confirmed to be related to an infec-
tion with B. canis, as blood analysis results (blood smear,
PCR and IFAT) for this animal were negative for B. canis
throughout the study period (see Table 2).
At each infestation time point, 12–16 % of ticks were
found to be infected with B. canis by PCR analysis. The
infection model was regarded as valid as all dogs in the
untreated control group were infected with B. canis, as
confirmed positive for B. canis by blood smear; for babe-
sial DNA by PCR analysis; and for B. canis antibodies by
IFAT after first or subsequent tick infestation. None of
the treated dogs became infected with B. canis during
the complete study duration, as confirmed by the ab-
sence of B. canis antibodies in the IFAT and a negative
test result for babesial DNA by PCR analysis on any of
Table 2 Number of dogs with increased rectal body
temperature (RBT) and number of dogs tested positive for B.
canis via blood smear, PCR and IFAT
Study group RBT Blood smear PCR IFAT
≥39.4 °C [POS] [POS] [POS]
Untreated control [n] 19/27 27/27 27/27 27/27
Treatment groupa [n] 1b/8 0/8 0/8 0/8
aoral treatment with fluralaner chewable tablets
bone dog had a RBT of 39.8 °C once 17 days after treatment
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after the last tick infestation (see Table 2). A 100 %
preventive effect against the transmission of B. canis by
infected D. reticulatus ticks was achieved after single
oral fluralaner treatment (see Table 3).
Discussion
The blocking of pathogen transmission (preventive ef-
fect) to dogs through the bite of vector ticks has become
an increased demand of pet owners and veterinarians in
the evaluation of the capacity of anti-tick compounds.
Canine babesiosis is one of the clinically most significant
and eminent tick-borne diseases [5], and was therefore
used as study model to determine the ability of fluralaner
to prevent the transmission of B. canis by infected D. reti-
culatus ticks. B. canis protozoa infect the red blood cells,
causing mild to severe disease with different severities in
clinical signs until death, if untreated. For this reason,
dogs in the untreated control group were immediately res-
cue treated after they had been tested positive by blood
smear. For these rescue-treated dogs, replacement dogs
were included, to maintain a sufficient number of at least
6 dogs in the control group for statistical analysis, as re-
quired by the guideline for evaluating the efficacy of para-
siticides for the treatment, prevention and control of flea
and tick infestations on dogs and cats [11].
Fluralaner is the first orally-administered compound
leading to systemic activity with an efficacy duration
over 12 weeks against ticks and fleas [8, 12]. Until 2014,
tick control compounds for dogs were available as spot-
ons, sprays or collars exhibiting its tick-killing efficacy
via blood meal and/or contact exposure/repellency [13].
In the speed of kill studies from Wengenmayer et al. [9],Table 3 Preventive effect against the transmission of B. canis by
D. reticulatus ticks
Untreated control Treatment groupa
Infected [n] 27/27 0/8
Non-infected [n] 0/27 8/8
Infected [%] 100 0
Prevention [%] - 100
p-Value - 0.0002
aoral treatment with fluralaner chewable tabletsit was demonstrated that orally-administered fluralaner
starts to kill ticks present on the dog as early as 4 h
(89.6 %), showing almost complete tick-killing efficacy
within 12 h after treatment over the entire 12-week period
of efficacy. These results are confirmed in this study by
the excellent efficacy results against ticks (see Table 1). As
fluralaner elicits its primary action through feeding activ-
ity, the protective effect of fluralaner is less obvious. The
efficacy of fluralaner depends on ticks attaching to the
host’s skin and commencing feeding, thereby ingesting the
active compound before being killed [8]. The transmission
time of B. canis from infected D. reticulatus ticks is given
by Heile et al. [14] with 48–72 h after tick attachment.
The tick’s attachment to the host’s skin starts the matur-
ation of the sporozoites located in the salivary glands of
the tick. A few days later after the tick has attached,
pathogen transmission through the saliva from the tick
causes host infection [15]. Due to its rapid tick-killing
effect, fluralaner effectively prevented the transmission of
B. canis from infected D. reticulatus ticks to the dogs
(Table 3). Fluralaner chewable tablets demonstrated an ef-
ficacy against ticks between 99.2 and 100 % over the entire
12-weeks study duration.
An active ingredient with a longer re-treatment inter-
val such as fluralaner reduces the risk of treatment
failure as a consequence of poor owner compliance with
monthly treatment recommendations. Owner compli-
ance is an important component of successful control
and prevention of tick infestations during tick season.
This study demonstrated that treatment with fluralaner
chewable tablet is not only effective against ticks and
protects the dog against pathogen transmission, but also
remains effective over a 12-week period following treat-
ment. Moreover, in addition to its efficacy against D.
reticulatus, fluralaner is effective for the same period of
time against other ticks and fleas that may concomi-
tantly infest these animals [12, 16].Conclusions
Single oral administration of fluralaner chewable tablets
(Bravecto™) to dogs prevented the transmission of B. canis
by infected D. reticulatus ticks by 100 % over 12 weeks.
An efficacy against ticks between 99.2 and 100 % was
achieved over the entire 12-week study duration. The long
re-treatment interval of fluralaner chewable tablets offers
more convenience over monthly tick-control treatments,
with a potential compliance advantage.Competing interests
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